The role of the Biostatistics Core is to support the investigators of the SPORE in Prostate Cancer in their research efforts, including laboratory experiments and the design and analysis of clinical trials. In preclinical studies, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this review, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, a randomization procedure if necessary, analysis plans, and a targeted sample size justified in probabilistic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol.
The specific aims of the Biostatistics Core are to:
Aim 1 : Contribute to the design and analysis of laboratory-based prostate cancer research Aim 2: Contribute to the design and analysis of clinical studies in prostate cancer Aim 3: Develop statistical methodology that will assist in the advancement of prostate cancer research

Public Health Relevance

The Biostatistics Core assists the research efforts of the MSKCC SPORE in Prostate Cancer investigators, contributing to the design and analysis of clinical and laboratory research and the development of valid conclusions. The core provides statistical analysis and consultancy as well as ongoing quality assurance. The core has also established a data quality working group to improve the quality of SPORE data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092629-14
Application #
8730092
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Han, SoHyun; Stoyanova, Radka; Lee, Hansol et al. (2018) Automation of pattern recognition analysis of dynamic contrast-enhanced MRI data to characterize intratumoral vascular heterogeneity. Magn Reson Med 79:1736-1744
Vickers, Andrew J; Steineck, Gunnar (2018) Prognosis, Effect Modification, and Mediation. Eur Urol 74:243-245
Kinsella, Netty; Helleman, Jozien; Bruinsma, Sophie et al. (2018) Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol 7:83-97
Hieronymus, Haley; Murali, Rajmohan; Tin, Amy et al. (2018) Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7:
Scher, Howard I; Graf, Ryon P; Schreiber, Nicole A et al. (2018) Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. JAMA Oncol 4:1179-1186
Bielski, Craig M; Zehir, Ahmet; Penson, Alexander V et al. (2018) Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet 50:1189-1195
Luo, Jun; Attard, Gerhardt; Balk, Steven P et al. (2018) Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol 73:715-723
Settleman, Jeffrey; Sawyers, Charles L; Hunter, Tony (2018) Challenges in validating candidate therapeutic targets in cancer. Elife 7:
Miyazawa, Miki; Subbaramaiah, Kotha; Bhardwaj, Priya et al. (2018) Pioglitazone Inhibits Periprostatic White Adipose Tissue Inflammation in Obese Mice. Cancer Prev Res (Phila) 11:215-226
Graham, Laura; Banda, Kalyan; Torres, Alba et al. (2018) A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest New Drugs 36:458-467

Showing the most recent 10 out of 505 publications